Global Streptococcal Infection Rapid Test Market Size By Type (Product Type I, Product Type II), By Application (Application I, Application II), By Region, And Segment Forecasts, 2023 to 2032

The Global Streptococcal Infection Rapid Test Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.0 billion by 2031, growing at a CAGR of 7.8% during the forecast period of 2023–2031. This market is witnessing robust growth due to the rising global prevalence of streptococcal infections, the increasing demand for point-of-care diagnostics, and advancements in rapid test technologies. Streptococcal rapid diagnostic tests (RDTs) enable quick and accurate detection of Group A and Group B streptococcal bacteria, significantly improving early intervention and treatment outcomes, especially in primary care and pediatric settings.

Drivers

1. Rising Prevalence of Streptococcal Infections:

Group A Streptococcus (GAS) is a common bacterial pathogen responsible for illnesses ranging from pharyngitis to life-threatening invasive diseases. The growing incidence of strep throat and related complications globally is significantly boosting demand for rapid diagnostic tools.

2. Shift Towards Point-of-Care Testing (POCT):

The increasing focus on early and convenient disease diagnosis is accelerating the adoption of POCT solutions. Rapid streptococcal tests are now widely used in clinics, emergency departments, and even pharmacies due to their quick turnaround times and ease of use.

3. Technological Advancements in Rapid Testing:

Innovations in lateral flow immunoassays and molecular testing platforms have improved the sensitivity and specificity of strep tests. These advancements are enhancing physician confidence and supporting broader adoption in healthcare systems.

Restraints

1. False Negatives in Low-Sensitivity Tests:

Although rapid strep tests offer convenience, concerns over diagnostic accuracy in low-sensitivity models can lead to false negatives, delaying appropriate treatment and undermining trust in the test's reliability.

2. Regulatory and Reimbursement Challenges:

Inconsistent regulatory frameworks across countries and lack of reimbursement for certain rapid diagnostic tests in developing regions can hinder market growth.

Opportunity

1. Expansion in Home-Based and Self-Testing Solutions:

The growing trend of home diagnostics, accelerated by the COVID-19 pandemic, presents a significant opportunity for the development and marketing of at-home streptococcal test kits.

2. Emerging Markets in Asia-Pacific and Latin America:

As healthcare infrastructure improves in emerging economies, there is rising awareness about infectious diseases and a growing demand for rapid, affordable diagnostic tools, opening lucrative market expansion avenues.

Market by System Type Insights

Based on system type, the Lateral Flow Assay (LFA) segment dominated the market in 2023, due to its affordability, simplicity, and widespread usage in clinical settings. However, the Molecular Diagnostic Kits segment is expected to witness the highest growth during the forecast period, driven by increasing demand for higher diagnostic accuracy and the introduction of CLIA-waived molecular POCT systems.

Market by End-Use Insights

The Hospitals & Clinics segment held the largest market share in 2023, accounting for over 45% of total revenue, attributed to high patient footfall and reliance on accurate diagnostic protocols. The Retail Pharmacies and At-Home Testing segment is poised for the fastest growth, supported by the rising consumer preference for accessible and fast diagnostic options.

Market by Regional Insights

In 2023, North America led the global streptococcal infection rapid test market, owing to high healthcare spending, favorable reimbursement policies, and widespread use of POCT in clinical practice. Asia-Pacific is projected to be the fastest-growing region, driven by increasing healthcare awareness, a rising burden of infectious diseases, and expanding access to rapid testing solutions in countries like China and India.

Competitive Scenario

Prominent players in the global streptococcal infection rapid test market include Abbott Laboratories, Quidel Corporation, Becton Dickinson and Company, Roche Diagnostics, Thermo Fisher Scientific, Cardinal Health, Meridian Bioscience, Bio-Rad Laboratories, and Sekisui Diagnostics. These companies are focusing on product innovation, expanding their POCT portfolios, and engaging in strategic partnerships to increase market share.

Recent Developments:

In 2023, Abbott Laboratories launched a new high-sensitivity lateral flow strep test designed for pediatric and urgent care settings.

In 2024, Quidel Corporation announced the expansion of its Sofia platform with a new molecular strep test, offering rapid results with laboratory-grade accuracy.

In 2025, Roche Diagnostics partnered with regional healthcare networks in Asia to distribute its point-of-care strep test kits, enhancing diagnostic accessibility.

Scope of Work – Global Streptococcal Infection Rapid Test Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.0 billion

CAGR (2023–2031) 7.8%